JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 6 No. 6 421-432
© 1965 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Osgood, E. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Osgood, E. E.

The Relative Dosage Required of Total Body X-Ray Vs Intravenous 32P for Equal Effectiveness Against Leukemic Cells of the Lymphocytic Series or Granulocytic Series in Chromic Leukemia1,2,

Edwin E. Osgood, M.D.3

Portland, Oregon

ABSTRACT

Data is presented which indicates that when comparisons are made at equal time intervals after the first dose, 1 mc of 32P given intravenously is equivalent in effect to 15 r of total-body x-ray irradiation, as herein defined, in its effect on the leukemic cells of the lymphocytic or the granulocytic series in chronic leukemia. With this ratio, clinical therapeutic effects were equal, as well as effects on the total cell population of the involved cell series. For the effects measured there is a definite threshold below which, in each patient, leukocyte counts and spleen and lymph node size are not reduced.

True radiation sensitivity of cell populations may differ greatly in different individuals and may change suddenly, either up or down, in the same individual at different times.

FOOTNOTES

1 Presented in part before the Eleventh Annual Meeting of the Society of Nuclear Medicine, Berkeley, California, June 19, 1964.

2 This work was supported in part by grants from the U. S. Atomic Energy Commission, Contract AT(45-1)-581; the U. S. Public Health Service, National Cancer Institute, Grant CA-6109; and the Medical Research Foundation of Oregon.

3 From the Division of Experimental Medicine, University of Oregon Medical School, Portland, Oregon 97201.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1965 by the Society of Nuclear Medicine.